Source: Annual Congress 2007 - Pulmonary circulation



Rating:

Share or cite this content

Citations should be made in the following way:
R. Syyed, A. Peacock (Glasgow, United Kingdom). Exercise induced pressure-flow profiles in the lung circulation have different responses in vasodilator responsive and non-responsive subjects with pulmonary hypertension (PH). Eur Respir J 2007; 30: Suppl. 51, 2101

Member's Comments

No comment yet.

Related content which might interest you: Contrasting cardiopulmonary responses to incremental exercise in patients with schistosomiasis-associated and idiopathic pulmonary arterial hypertension with similar resting hemodynamic impairment Source: Annual Congress 2011 - Physiology of human pulmonary hypertension Year: 2011 Effect of riociguat on haemodynamic parameters and exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009 Effects of hypoxia-induced chronic changes in pulmonary haemodynamics on the lung function and responsiveness in rats Source: Annual Congress 2009 - Experimental approaches in animals and modelling in humans Year: 2009 Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Comparison of exercise capacity and exercise haemodynamic relationships between severe group 3 pulmonary hypertension and pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 Pulmonary vascular response to exercise in heart-failure patients with pulmonary hypertension: role of a pre-capillary component Source: International Congress 2017 – Exercise and physiology in pulmonary hypertension Year: 2017 Haemodynamic effects of exercise therapy in stable, optimally treated pulmonary arterial hypertension Source: International Congress 2017 – Exercise and physiology in pulmonary hypertension Year: 2017 Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Haemodynamic responses to exercise in patients with COPD Source: Eur Respir J 2013; 41: 1031-1041 Year: 2013 Role of tadalafil in patients with hypoxia / lung disease induced (group 3) pulmonary hypertension Source: International Congress 2016 – Pulmonary hypertension: the clinic I Year: 2016 Impact of long-term oxygen therapy on systemic inflammation, morphological changes of red blood cells, pulmonary hemodynamics and diaphragm function in patients with chronic obstructive pulmonary disease. Source: International Congress 2018 – Integrated care and non-pharmacological management of COPD Year: 2018 Pulmonary artery pressure (PAP) reduction by systemic and inhaled nitroglycerin (NTG) in an isolated rabbit lung model of pulmonary hypertension (PH) Source: Eur Respir J 2003; 22: Suppl. 45, 270s Year: 2003 Acute vasodilator response in different forms of pre-capillary pulmonary hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013 Effects of oxygen supplementation during exercise on hemodynamic responses in patients with pulmonary arterial hypertension Source: Virtual Congress 2020 – New insights into evaluation and treatment of respiratory disease Year: 2020 Identification of individuals susceptible to high-altitude pulmonary oedema at low altitude Source: Eur Respir J 2005; 25: 545-551 Year: 2005 ‘Idiopathic‘ pulmonary arterial hypertension with preserved lung function but co-existing parenchymal abnormalities: Response to treatment and survival Source: Annual Congress 2012 - Pulmonary circulation: clinical databases and registries Year: 2012 Pulmonary arterial pressure response during exercise in COPD patients and healthy subjects Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009 Sitaxsentan for pulmonary arterial hypertension (PAH) patients with clinical deterioration or significantly abnormal liver function test on bosentan Source: Eur Respir J 2005; 26: Suppl. 49, 563s Year: 2005 Pulmonary artery pressure (PAP) is reduced by inhaled sodium nitroprusside (SNP) in an isolated lung model of pulmonary hypertension: comparison with systemic application Source: Eur Respir J 2002; 20: Suppl. 38, 4s Year: 2002 Acetazolamide and chronic hypoxia: effects on haemorheology and pulmonary haemodynamics Source: Eur Respir J 2012; 40: 1401-1409 Year: 2012